Influence of non-alcoholic malt beverages on urinary excretions of calcium and uric acid

Kwestan R. Muhammad; Snjawi A. Sultan; Salim K. Mohammed

doi:10.15218/zjms.2015.0039

Authors

Kwestan R. Muhammad Department of clinical biochemistry, college of health sciences, Hawler Medical University, Erbil, Iraq.
Snjawi A. Sultan Department of laboratory, Hawler Teaching Hospital, Erbil, Iraq.
Salim K. Mohammed Department of clinical biochemistry, college of health sciences, Hawler Medical University, Erbil, Iraq.

DOI:

https://doi.org/10.15218/zjms.2015.0039

Keywords:

uric acid, calcium, Barbican, urinary excretion

Abstract

Background and objective: Malt beverage without alcohol (Barbican) is an energy beverage which is regularly consumed by Muslim countries and substantial quantities are exported to the Gulf States and Middle East countries. Barbican is used widely by people whom alcohol is forbidden either on medical grounds or on religious aspects. The aim of this study was to assess the effect of short-term drinking of Barbican on urinary excretion of calcium and uric acid in normal young males in Erbil city.

Methods: Thirty healthy male volunteer subjects of 21-23 years age consumed 330 ml of Barbican® beverage per day for two successive days after cross design. The urinary calcium and urinary uric acid were evaluated before and after consumption.

Results: There was no statistically significant increase in urinary uric acid before and after consumption of Barbican beverage (P = 0.071). Urinary calcium significantly decreased after consumption of Barbican drink (P = 0.037).

Conclusion: Although many extrinsic and intrinsic factors influence formation of kidney stones and bone resorption, this study suggests that drinking of Barbican beverage may be helpful to prevent bone resorption and also to reduce risk of stone formation.

Metrics

Metrics Loading ...

References

EL-Naggar AY, Arida H, Montasser M, Hassan R. Measures affecting alcohol in malt beverages according to Islamic religion. J Am Sci 2012; 8(10):455-60.

Safreit D. Written communication from Brain Shrager, Midwest Research Institute, Cary, NC, to Dallas Safreit, U.S. Environmental Protection Agency, Research Triangle Park, NC; 1994.

Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. The Lancet 2007; 369(9566):1047-53.

Meyer, Jerold S, Quenzer LF. Psychopharmacology: Drugs, the Brain, and Behavior. Sunderland, Massachusetts: Sinauer Associates, Inc; 2005; P. 228.

Oscar-Berman M, Marinkovic K. Alcoholism and the brain: an overview. Alcohol Res Health 2003; 27(2):125-33.

Klatsky AL, Friedman GD. Alcohol and longevity. Am J of Public Health 1995; 58(1):16-8.

Penniston KL, Nakada SY. Diet and alternative therapies in the management of stone disease. Urol Clin N Am 2013; 40:31-46.

Shimizu T, Kitada H, Umeyama M, Hori H, Takasaki N. Noval evaluation of nephrolithiasis as a complication of gout: A cross-sectional study using helical computerized tomography. J Urology 2013; 189:1747-52.

Copelovitch L. Urolithiasis in children. Pediatr Clin N Am 2012; 59:881-96.

Frassetto L, Kohlstadt I. Treatment and prevention of kidney stones: An update. Am Fam Physician 2011; 84(11):1234-42.

Tiwari R, Campfield T, Wittcopp C, Braden G, Visintainer P, Reiter EO, et al. Metabolic Syndrome in Obese Adolescents is Associated with Risk for Nephrolithiasis. J Pediatr 2012; 160:615-20.

Sweeney DD, Tomazewski JJ, Ricchiuti DP, Averch TD. Effect of carbohydrate-electrolyte sports beverages on urinary stone risk factors. J Urology 2009; 182:992-7.

Meschi T, Nouvenne A, Borghi L. Lifestyle recommendations to reduce the risk of kidney stones. Urol Clin N Am 2011; 38(3):313-20.

Bagga HS, Chi T, Miller J, Stoller ML. New insights into the pathogenesis of renal calculi. Urol Clin N Am 2013; 40:1-12.

Eisner BH, Goldfarb DS, Pareek G. Pharmacologic treatment of kidney stone disease. Urol Clin N Am 2013; 40:21-30.

He J, Reilly M, Yang W, Chen j, Go AS, Lash JP, et al. Risk factors for coronary artery calcium among patients with chronic kidney disease (from the chronic renal insufficiency cohort study). Am J Cardiol 2012; 110:1735-41.

Barger-Lux MJ, Heaney RP. Caffeine and the calcium economy revisited. Osteoporosis Int 1995; 5:97-102.

Ross AC, Taylor CL, Yaktine AL, Del HB Vitamin D and Calcium: updated dietary reference intakes. Available at (http://www.hc-sc.gc.ca/fn-an/nutrition/vitamin/vita-d-eng.php) in 25 June 2014.

Goldfarb DS, Arowojolu O. Metabolic Evaluation of First-time and Recurrent Stone Formers. Urol Clin N Am 2013; 40:13-20.

Tietz NW. Text book of clinical chemistry. 3rd Ed. USA: WB Saunders; 1999.

Moorehead WR, Briggs HG. Clinical chemistry. USA: WB Saunders; 1974.

Fossati P, Prencipe L, Berti G. Use of 3, 5-dichloro-2-hydroxybenzene sulfonic acid/ 4 amino phenazone chromogenic system in direct enzymatic assays of uric acid in serum and urine. Clin Chem 1980; 26:227-31.

Daniel WW. Biostatistics: A foundation for analysis in the health science. 3rd Edition. USA: John Wiley and Sons; 1983.

Taylor EN, Curhan GC. Fructose consumption and the risk of kidney stones. Kidney Int 2008; 73:207-12.

Kok DJ, Papapoulos SE, Bijvoet OL. Excessive crystal agglomeration with low citrate excretion in recurrent stone-formers. Lancet 1986; 1:1056-8.

Seltzer MA, Low RK, McDonald M, Shami GS, Stoller ML. Dietary manipulation with lemonade to treat hypocitraturic calcium nephrolithiasis. J Urol 1996; 156:907-9.

Kang DE, Sur RL, Haleblian GE, Fitzsimons NJ, Borawski KM, Preminger GM. Long-term lemonade based dietary manipulation in patients with hypocitraturic nephrolithiasis. J Urol 2007; 177:1358-62.

Heaney RP, Rafferty K. Carbonated beverages and urinary calcium excretion. Am J Clin Nutr 2001; 74(3):343-7.

Bhowmik D, Kumar S, Paswan S, Sirvastava S. Tomato - A natural medicine and its health benefits. Phyto J 2012: 1(1):33-43.

Knight J, Assimos DG, Easter L, Holms RP. Metabolism of fructose to oxalate and glycolate. Horm Metab Res 2010; 42(12):868-73.

Eisner BH, Asplin JR, Goldfarb DS, Ahmad A, Stoller ML. Citrate, malate and alkali content in commonly consumed diet sodas: Implications for Nephroliathiasis Treatment. J Urology 2010; 183:2419-23.

Kovacevic L, Christensen CW, Edwards L, Sadaps M, Lakshmanan Y. From hypercalciuria to hypocitraturia- A shifting trend in pediatric urolithiasis? J Urology 2012; 188:1623-7.

Zuckerman JM, Assimos DG. Hypocitraturia: pathophysiology and medical management. Rev Urol 2009; 11:134-44.

Baraf HM, Adamson HS, Basile TC, Cole L, Doghramaji B, Guadagnoli PP, et al. Recommendations for the diagnosis and management of gout and hyperurecemia. The physician and Sports Medicine 2011; 39(4): 98-123.

Taylor EN, Stampfer MJ, Mount DB, Curhan GC. Re: DASH-style diet and 24-hour urine composition. J Urology 2011; 185:548-50.